These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32388462)

  • 1. A glimpse into the eye of the COVID-19 cytokine storm.
    Kuppalli K; Rasmussen AL
    EBioMedicine; 2020 May; 55():102789. PubMed ID: 32388462
    [No Abstract]   [Full Text] [Related]  

  • 2. Could SARS-CoV-2-Induced Hyperinflammation Magnify the Severity of Coronavirus Disease (CoViD-19) Leading to Acute Respiratory Distress Syndrome?
    Girija ASS; Shankar EM; Larsson M
    Front Immunol; 2020; 11():1206. PubMed ID: 32574269
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
    Yao Z; Zheng Z; Wu K; Junhua Z
    Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the T cell response to COVID-19.
    Li J; Wang J; Kang AS; Sacitharan PK
    Signal Transduct Target Ther; 2020 Jul; 5(1):112. PubMed ID: 32616709
    [No Abstract]   [Full Text] [Related]  

  • 5. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).
    Al-Tawfiq JA
    Travel Med Infect Dis; 2020; 35():101608. PubMed ID: 32114075
    [No Abstract]   [Full Text] [Related]  

  • 6. [Structure of SARS-CoV-2 and treatment of COVID-19].
    Chen HX; Chen ZH; Shen HH
    Sheng Li Xue Bao; 2020 Oct; 72(5):617-630. PubMed ID: 33106832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical distancing, face masks, and eye protection for prevention of COVID-19.
    MacIntyre CR; Wang Q
    Lancet; 2020 Jun; 395(10242):1950-1951. PubMed ID: 32497511
    [No Abstract]   [Full Text] [Related]  

  • 9. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cluster of pneumonia associated with the SARS-Cov-2 outside of Wuhan related to a house-warming banquet.
    Liu L; Quan J; Lv J; Long S; Hu W; Zhuge H; Zhou Z; Zhao D
    J Infect; 2020 Jul; 81(1):147-178. PubMed ID: 32283138
    [No Abstract]   [Full Text] [Related]  

  • 11. T cells in COVID-19 - united in diversity.
    Swadling L; Maini MK
    Nat Immunol; 2020 Nov; 21(11):1307-1308. PubMed ID: 32895541
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection.
    de Melo AF; Homem-de-Mello M
    Crit Care; 2020 Aug; 24(1):500. PubMed ID: 32792018
    [No Abstract]   [Full Text] [Related]  

  • 13. From SARS-CoV to SARS-CoV-2: The response and challenge of forensic infectious disease autopsy.
    Wang HJ
    Fa Yi Xue Za Zhi; 2020 Feb; 36(1):1-3. PubMed ID: 32198983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and issues of SARS-CoV-2 pool testing.
    Eberhardt JN; Breuckmann NP; Eberhardt CS
    Lancet Infect Dis; 2020 Nov; 20(11):1233-1234. PubMed ID: 32679088
    [No Abstract]   [Full Text] [Related]  

  • 15. Challenges and issues of SARS-CoV-2 pool testing.
    Mishra B; Behera B; Mohanty M; Ravindra A; Ranjan J
    Lancet Infect Dis; 2020 Nov; 20(11):1233. PubMed ID: 32679083
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges and issues of SARS-CoV-2 pool testing.
    Lee J; Kim SY; Sung H; Lee SW; Lee H; Roh KH; Yoo CK; Hong KH
    Lancet Infect Dis; 2020 Nov; 20(11):1232-1233. PubMed ID: 32679080
    [No Abstract]   [Full Text] [Related]  

  • 17. SARS-COV-2 pandemic: the significance of underlying conditions.
    Dolk H
    Occup Med (Lond); 2020 Jul; 70(5):352-353. PubMed ID: 32428215
    [No Abstract]   [Full Text] [Related]  

  • 18. Duration for carrying SARS-CoV-2 in COVID-19 patients.
    Du X; Yu X; Li Q; Li X; Qin T; Luo Q; Wang M; Jiang M; Bai L; Wang X; Pan Y
    J Infect; 2020 Jul; 81(1):e78-e79. PubMed ID: 32283161
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 and cardiovascular disorder.
    Mungmungpuntipantip R; Wiwanitkit V
    Minerva Cardioangiol; 2020 Jun; 68(3):277. PubMed ID: 32319272
    [No Abstract]   [Full Text] [Related]  

  • 20. Duration of SARS-CoV-2 viral RNA in asymptomatic carriers.
    Yan X; Han X; Fan Y; Fang Z; Long D; Zhu Y
    Crit Care; 2020 May; 24(1):245. PubMed ID: 32448332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.